Insulet (PODD) Cut to Buy at ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Insulet (NASDAQ:PODD) from a strong-buy rating to a buy rating in a report released on Monday.

Several other equities research analysts have also commented on PODD. Leerink Swann restated an outperform rating and set a $100.00 target price (down from $110.00) on shares of Insulet in a research report on Thursday, January 3rd. Oppenheimer set a $100.00 target price on shares of Insulet and gave the stock a hold rating in a research report on Friday, November 2nd. BidaskClub lowered shares of Insulet from a strong-buy rating to a buy rating in a research report on Tuesday, September 25th. UBS Group assumed coverage on shares of Insulet in a research report on Tuesday, November 27th. They set a buy rating and a $105.00 target price on the stock. Finally, Morgan Stanley decreased their target price on shares of Insulet from $105.00 to $90.00 and set an equal weight rating on the stock in a research report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $99.87.

PODD traded down $1.25 during trading on Monday, hitting $73.63. The stock had a trading volume of 7,893 shares, compared to its average volume of 1,112,644. The company has a debt-to-equity ratio of 2.95, a quick ratio of 3.99 and a current ratio of 4.58. The stock has a market capitalization of $4.56 billion, a P/E ratio of -159.76 and a beta of 1.56. Insulet has a twelve month low of $70.80 and a twelve month high of $108.90.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. The company had revenue of $151.10 million for the quarter, compared to analysts’ expectations of $148.82 million. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. Insulet’s revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) EPS. Sell-side analysts predict that Insulet will post -0.05 EPS for the current year.

In related news, SVP David Colleran sold 6,113 shares of the business’s stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $80.41, for a total value of $491,546.33. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Aiman Abdel-Malek sold 602 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $88.58, for a total transaction of $53,325.16. The disclosure for this sale can be found here. Insiders sold a total of 8,451 shares of company stock worth $691,834 over the last quarter. Insiders own 3.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in Insulet by 0.4% in the 3rd quarter. FMR LLC now owns 8,778,854 shares of the medical instruments supplier’s stock valued at $930,119,000 after purchasing an additional 37,973 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Insulet by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,053,657 shares of the medical instruments supplier’s stock valued at $535,434,000 after purchasing an additional 84,209 shares in the last quarter. Vanguard Group Inc lifted its holdings in Insulet by 1.7% in the 3rd quarter. Vanguard Group Inc now owns 5,053,657 shares of the medical instruments supplier’s stock valued at $535,434,000 after purchasing an additional 84,209 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Insulet by 57.4% in the 3rd quarter. William Blair Investment Management LLC now owns 1,871,961 shares of the medical instruments supplier’s stock valued at $198,334,000 after purchasing an additional 682,393 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in Insulet by 5.6% in the 3rd quarter. Clearbridge Investments LLC now owns 1,823,750 shares of the medical instruments supplier’s stock valued at $193,226,000 after purchasing an additional 96,266 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Read More: What is the NASDAQ?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Village Farms International  Trading 20.4% Higher
Village Farms International Trading 20.4% Higher
Enablence Technologies  Trading Down 16.7%
Enablence Technologies Trading Down 16.7%
Q4 2019 EPS Estimates for Citizens Financial Group Inc  Lowered by Wedbush
Q4 2019 EPS Estimates for Citizens Financial Group Inc Lowered by Wedbush
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial


Leave a Reply

 
© 2006-2019 Zolmax.